Some aspects of the biology of the stargazer mountain catfish,Amphilius uranoscopus (pfeffer); (Siluriformes: Amphiliidae) indigenous to Kenya streams

A study on some biological parameters of the mountain catfish, Amphilius uranoscopus Pfeffer 1889 (Silurifomes: Amphiliidae), was carried out in the Thego stream on the slopes of Mount Kenya from February to December 2002. Physical and chemical profiles of the Thego show that the water quality parameters is typical of high altitude streams with temperatures rarely exceeding 18°C, DO ranging from 7.9 to 8.2 mg l^?1 and relatively high conductivity (97–137 μS cm^?1) typical of perturbed lotic environments. A total of 1010 fish were caught by an electro‐fisher, with sizes ranging between 8 and 24 cm fork length. The population structure had a unimodal distribution with maxima at 14–16 cm. The length–weight relationship showed relatively narrow range in the slope ranging from 2.61 in April to 2.98 in February 2002, thereby suggesting isometric growth pattern. The fitted growth pattern of A. uranoscopus showed an asymptotic length (L_∞) of 28.5 cm and a growth curvature (K) of 0.56 year^?1 resulting in an estimated natural mortality coefficient (M) of 0.90 year^?1. The Fulton’s condition factor (K) was also relatively stable with a peak in April (0.92 ± 0.21) and lowest value in June (0.86 ± 0.10). As A. uranoscopus is not under commercial exploitation, the seemingly depressed population is possibly attributed to the introduced exotic rainbow trout that heavily predates on the species and environmental perturbations arising from changes in land use. The implications of such changes on A. uranoscopus are discussed.     

Randomized Controlled Field Trial to Assess the Immunogenicity and Safety of Rift Valley Fever Clone 13 Vaccine in Livestock

BackgroundAlthough livestock vaccination is effective in preventing Rift Valley fever (RVF) epidemics, there are concerns about safety and effectiveness of the only commercially available RVF Smithburn vaccine. We conducted a randomized controlled field trial to evaluate the immunogenicity and safety of the new RVF Clone 13 vaccine, recently registered in South Africa.MethodsIn a blinded randomized controlled field trial, 404 animals (85 cattle, 168 sheep, and 151 goats) in three farms in Kenya were divided into three groups. Group A included males and non-pregnant females that were randomized and assigned to two groups; one vaccinated with RVF Clone 13 and the other given placebo. Groups B included animals in 1^st half of pregnancy, and group C animals in 2^nd half of pregnancy, which were also randomized and either vaccinated and given placebo. Animals were monitored for one year and virus antibodies titers assessed on days 14, 28, 56, 183 and 365.ResultsIn vaccinated goats (N = 72), 72% developed anti-RVF virus IgM antibodies and 97% neutralizing IgG antibodies. In vaccinated sheep (N = 77), 84% developed IgM and 91% neutralizing IgG antibodies. Vaccinated cattle (N = 42) did not develop IgM antibodies but 67% developed neutralizing IgG antibodies. At day 14 post-vaccination, the odds of being seropositive for IgG in the vaccine group was 3.6 (95% CI, 1.5 – 9.2) in cattle, 90.0 (95% CI, 25.1 – 579.2) in goats, and 40.0 (95% CI, 16.5 – 110.5) in sheep. Abortion was observed in one vaccinated goat but histopathologic analysis did not indicate RVF virus infection. There was no evidence of teratogenicity in vaccinated or placebo animals.ConclusionsThe results suggest RVF Clone 13 vaccine is safe to use and has high (>90%) immunogenicity in sheep and goats but moderate (> 65%) immunogenicity in cattle.     

Predictive Factors and Risk Mapping for Rift Valley Fever Epidemics in Kenya

Background

To-date, Rift Valley fever (RVF) outbreaks have occurred in 38 of the 69 administrative districts in Kenya. Using surveillance records collected between 1951 and 2007, we determined the risk of exposure and outcome of an RVF outbreak, examined the ecological and climatic factors associated with the outbreaks, and used these data to develop an RVF risk map for Kenya.

Methods

Exposure to RVF was evaluated as the proportion of the total outbreak years that each district was involved in prior epizootics, whereas risk of outcome was assessed as severity of observed disease in humans and animals for each district. A probability-impact weighted score (1 to 9) of the combined exposure and outcome risks was used to classify a district as high (score ≥ 5) or medium (score ≥2 - <5) risk, a classification that was subsequently subjected to expert group analysis for final risk level determination at the division levels (total = 391 divisions). Divisions that never reported RVF disease (score < 2) were classified as low risk. Using data from the 2006/07 RVF outbreak, the predictive risk factors for an RVF outbreak were identified. The predictive probabilities from the model were further used to develop an RVF risk map for Kenya.

Results

The final output was a RVF risk map that classified 101 of 391 divisions (26%) located in 21 districts as high risk, and 100 of 391 divisions (26%) located in 35 districts as medium risk and 190 divisions (48%) as low risk, including all 97 divisions in Nyanza and Western provinces. The risk of RVF was positively associated with Normalized Difference Vegetation Index (NDVI), low altitude below 1000m and high precipitation in areas with solonertz, luvisols and vertisols soil types (p <0.05).

Conclusion

RVF risk map serves as an important tool for developing and deploying prevention and control measures against the disease.